CA2346954A1 - Amelioration des performances physiques par l'augmentation de la production ou de l'activite du monoxyde d'azote endogene - Google Patents

Amelioration des performances physiques par l'augmentation de la production ou de l'activite du monoxyde d'azote endogene Download PDF

Info

Publication number
CA2346954A1
CA2346954A1 CA002346954A CA2346954A CA2346954A1 CA 2346954 A1 CA2346954 A1 CA 2346954A1 CA 002346954 A CA002346954 A CA 002346954A CA 2346954 A CA2346954 A CA 2346954A CA 2346954 A1 CA2346954 A1 CA 2346954A1
Authority
CA
Canada
Prior art keywords
mice
exercise
mammal
enhancing
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002346954A
Other languages
English (en)
Inventor
John P. Cooke
Andrew J. Maxwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22294659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2346954(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2346954A1 publication Critical patent/CA2346954A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Abstract

Des précurseurs NO sont administrés à haute dose à un sujet en association à un régime, en vue d'améliorer ses performances physiques. Plus particulièrement, L-arginine et L-lysine, en augmentant la production du NO endothélial, peuvent assurer une plus grande capacité respiratoire et de meilleures performances physiques.
CA002346954A 1998-06-23 1999-05-28 Amelioration des performances physiques par l'augmentation de la production ou de l'activite du monoxyde d'azote endogene Abandoned CA2346954A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/103,340 US6117872A (en) 1998-06-23 1998-06-23 Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity
US09/103,340 1998-06-23
PCT/US1999/012022 WO1999066921A1 (fr) 1998-06-23 1999-05-28 Amelioration des performances physiques par l'augmentation de la production ou de l'activite du monoxyde d'azote endogene

Publications (1)

Publication Number Publication Date
CA2346954A1 true CA2346954A1 (fr) 1999-12-29

Family

ID=22294659

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002346954A Abandoned CA2346954A1 (fr) 1998-06-23 1999-05-28 Amelioration des performances physiques par l'augmentation de la production ou de l'activite du monoxyde d'azote endogene

Country Status (5)

Country Link
US (1) US6117872A (fr)
EP (1) EP1105115A1 (fr)
AU (1) AU4322399A (fr)
CA (1) CA2346954A1 (fr)
WO (1) WO1999066921A1 (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US8128955B2 (en) * 1996-05-31 2012-03-06 The Original Creatine Patent Company Food compositions containing creatine
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
AU3221599A (en) * 1998-04-03 1999-10-25 Daily Wellness Company, The Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
AU4013900A (en) * 1999-03-19 2000-10-09 Enos Pharmaceuticals, Inc. Increasing cerebral bioavailability of drugs
US6465463B1 (en) 1999-09-08 2002-10-15 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US6612306B1 (en) 1999-10-13 2003-09-02 Healthetech, Inc. Respiratory nitric oxide meter
CZ20021346A3 (cs) * 1999-10-18 2003-06-18 Muscletech Research And Development Inc. Potravinový doplněk pro růst svalové hmoty a síly
US6784209B1 (en) * 1999-10-18 2004-08-31 Muscletech Research And Development Inc. Food supplement for increasing lean mass and strength
US7537785B2 (en) * 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
US7235237B2 (en) * 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7708989B2 (en) * 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
AU780261B2 (en) 1999-10-29 2005-03-10 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US6544994B2 (en) * 2000-06-07 2003-04-08 Eprov Ag Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase
US20030212136A1 (en) * 2001-09-14 2003-11-13 Vennerstrom Jonathan L. Creatine ester pronutrient compounds and formulations
US9833427B2 (en) * 2000-09-14 2017-12-05 Board Of Regents Of The University Of Nebraska Creatine ester anti-inflammatory compounds and formulations
US20030212130A1 (en) * 2000-09-14 2003-11-13 Miller Donald W. Creatine ester anti-inflammatory compounds and formulations
NZ524510A (en) * 2000-09-14 2005-08-26 Univ Nebraska Creatine ester pronutrient compounds and formulations
AU2001296456A1 (en) 2000-09-29 2002-04-08 Healthetech, Inc. Indirect calorimetry system
US6497885B2 (en) 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
US6989164B2 (en) 2000-12-22 2006-01-24 The Daily Wellness Company Method and composition for improving male fertility health
US20060062864A1 (en) * 2000-12-28 2006-03-23 Mccleary Edward L Weight loss composition and method
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US6537992B2 (en) * 2001-01-05 2003-03-25 John D. Parker Regulation of organic nitrate tolerance
US6964969B2 (en) 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20060014773A1 (en) * 2001-04-19 2006-01-19 Mccleary Edward L Mental agility lozenge, edible strip, food or drink
US7449451B2 (en) * 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
US6849613B2 (en) 2001-08-29 2005-02-01 Kedar N. Prasad Multiple antioxidant micronutrients
US6444237B1 (en) 2001-09-13 2002-09-03 Pamela A. Heleen Herbal composition for enhancing sexual response
US7740878B2 (en) * 2001-10-22 2010-06-22 Danisco A/S Use of betaine to enhance exercise performance
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US7033602B1 (en) 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US7794743B2 (en) 2002-06-21 2010-09-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
WO2004037203A2 (fr) * 2002-10-24 2004-05-06 Enos Pharmaceuticals, Inc. Preparations de l-arginine a liberation prolongee et procedes de fabrication et d'utilisation de celles-ci
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
WO2004071437A2 (fr) * 2003-02-07 2004-08-26 Barmensen, Inc. Compositions pour ameliorer la sensibilite sexuelle
JP2007521324A (ja) * 2003-09-29 2007-08-02 エノス ファーマシューティカルズ， インク． 徐放性ｌ−アルギニン調合物並びにその製造法及び使用法
CA2545584C (fr) 2003-11-17 2012-10-23 Biomarin Pharmaceutical Inc. Methodes et compositions destinees au traitement de troubles metaboliques
US20050119222A1 (en) 2003-12-01 2005-06-02 The Iams Company Compositions comprising fermentable fiber which are adapted for use by a companion animal and kits and methods of their use
US20050118234A1 (en) * 2003-12-01 2005-06-02 The Iams Company Methods and kits related to administration of a fructooligosaccharide
WO2005081964A2 (fr) * 2004-02-23 2005-09-09 Strategic Science & Technologies, Llc Administration topique d'un donneur d'oxyde nitrique, destinee a ameliorer l'aspect du corps et de la peau
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
WO2005102307A2 (fr) 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Effets benefiques de l'augmentation du debit sanguin local
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
EP1778267A4 (fr) * 2004-07-16 2010-01-06 Nitromed Inc Compositions et methodes associees a l'insuffisance cardiaque
BRPI0517088A (pt) * 2004-11-17 2008-09-30 Biomarin Pharm Inc formulação de comprimido estável
EP1984010A4 (fr) * 2006-02-17 2010-09-08 Nitromed Inc Procédés utilisant des composés d'hydralazine et du dinitrate d'isosorbide ou du mononitrate d'isosorbide
US20090306081A1 (en) * 2006-05-16 2009-12-10 Letts L Gordon Solid Dosage Formulations of Hydralazine Compounds and Nitric Oxide Donor Compounds
US8883814B2 (en) 2006-06-05 2014-11-11 Keyview Labs, Inc. Compositions and methods for enhancing brain function
US10105406B2 (en) 2006-06-05 2018-10-23 Keyview Labs, Inc. Compositions and methods for enhancing brain function using acetyl-L-carnitine, huperzine A, Ginkgo biloba, and vitamin B complex
US9308232B2 (en) 2006-06-05 2016-04-12 Keyview Labs, Inc. Compositions and methods for enhancing brain function
US20070281961A1 (en) * 2006-06-05 2007-12-06 Brite Age Modified Compositions And Methods For Enhancing Brain Function
US8071610B2 (en) * 2006-06-05 2011-12-06 Josh Reynolds Compositions and methods for enhancing brain function
US10105405B2 (en) 2006-06-05 2018-10-23 Keyview Labs, Inc. Compositions and methods for enhancing brain function using acetyl-L-carnitine, huperzine A and ginkgo biloba
JP2010514804A (ja) * 2006-12-29 2010-05-06 ザ・ソーク・インスティチュート・フォー・バイオロジカル・スタディーズ 運動能力を高めるための方法
ES2618655T3 (es) 2007-02-26 2017-06-21 Heartbeet Ltd. Composición que mejora el rendimiento y uso de la misma
US11759477B2 (en) 2007-02-26 2023-09-19 Heartbeet Ltd. Compositions of nitrates and methods of use thereof
US10821132B2 (en) 2007-02-26 2020-11-03 Heartbeet Ltd Compositions of nitrates and methods of use thereof
US10842813B2 (en) 2007-02-26 2020-11-24 Heartbeet Ltd Compositions of nitrates and methods of use thereof
US10835555B2 (en) 2007-02-26 2020-11-17 Heartbeet Ltd Compositions of nitrates and methods of use thereof
CA2678097C (fr) 2007-02-26 2023-03-14 Jon Lundberg Nouvelle utilisation de nitrites et de nitrates et compositions les renfermant
US20110237670A1 (en) * 2008-12-12 2011-09-29 Daniel Klamer Improvement of normal cognitive function
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
BRPI0925099A2 (pt) 2009-06-24 2018-10-16 Strategic Science & Tech Llc composição tópica contendo ibuprofeno
EP2445493A1 (fr) 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Composition topique contenant du naproxène
IT1402330B1 (it) * 2010-09-03 2013-08-30 Poli Integratore alimentare
CN103429247A (zh) 2010-12-29 2013-12-04 战略科学与技术有限责任公司 勃起功能障碍和其它适应症的治疗
WO2012092523A1 (fr) 2010-12-29 2012-07-05 Strategic Science & Technologies, Llc Systèmes et procédés de traitement d'allergies et autres indications
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US10499682B2 (en) 2014-08-25 2019-12-10 New Age Beverage Corporation Micronutrient formulation in electronic cigarettes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871550A (en) * 1986-09-05 1989-10-03 Millman Phillip L Nutrient composition for athletes and method of making and using the same
SU1653714A1 (ru) * 1988-03-17 1991-06-07 Всесоюзный Научно-Исследовательский Институт Коневодства Способ кормлени спортивных лошадей
US5026721A (en) * 1989-06-05 1991-06-25 Dudrick Stanley J Amino acid nutritional supplement and regimen for enhancing physical performance through sound nutrition
AU1780395A (en) * 1994-05-02 1995-11-09 Omeara (Proprietary) Limited Amino acid, carnitine and magnesium supplementation
GB9510037D0 (en) * 1995-05-18 1995-07-12 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
CZ4392U1 (cs) * 1995-11-16 1996-02-07 Nutrend D.S., A.S. Multikomponentní výživový doplněk
DE19720818A1 (de) * 1996-11-15 1998-05-20 Sportmedizin Team Muenchen Arz Zusammensetzung zur Leistungsförderung bei oder Regeneration nach sportlicher Tätigkeit, ihre Herstellung und Verwendung als diätetisches Lebensmittel

Also Published As

Publication number Publication date
EP1105115A1 (fr) 2001-06-13
WO1999066921A1 (fr) 1999-12-29
AU4322399A (en) 2000-01-10
US6117872A (en) 2000-09-12

Similar Documents

Publication Publication Date Title
US6117872A (en) Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity
Papadia et al. Citrulline in health and disease. Review on human studies
Gonzalez et al. Effects of citrulline supplementation on exercise performance in humans: A review of the current literature
Legault et al. The influence of oral L-glutamine supplementation on muscle strength recovery and soreness following unilateral knee extension eccentric exercise
Stevens et al. High-intensity dynamic human muscle performance enhanced by a metabolic intervention
Alvares et al. L-Arginine as a potential ergogenic aidin healthy subjects
Fielding et al. Enhanced protein breakdown after eccentric exercise in young and older men
Mikulski et al. Effects of supplementation with branched chain amino acids and ornithine aspartate on plasma ammonia and central fatigue during exercise in healthy men
Sunderland et al. VO^ sub 2^ MAX AND VENTILATORY THRESHOLD OF TRAINED CYCLISTS ARE NOT AFFECTED BY 28-DAY L-ARGININE SUPPLEMENTATION
US20160303177A1 (en) Nutritional supplement
Pitkänen et al. Leucine supplementation does not enhance acute strength or running performance but affects serum amino acid concentration
US20160303176A1 (en) Nutritional supplement
Castell et al. The relation between glutamine and the immunodepression observed in exercise
Tarnopolsky et al. Nutrition and exercise in Pompe disease
Gurton et al. Sodium bicarbonate ingestion improves time-to-exhaustion cycling performance and alters estimated energy system contribution: a dose-response investigation
JP2004505056A (ja) 心血管の機能を向上する為の組成物及び方法
Swan et al. Substrate utilization and work efficiency during submaximal exercise in vitamin C depleted-repleted adults
US20080108698A1 (en) Nutrient Supplement and Use of the Same
Piattoly L-glutamine supplementation: Effects on recovery from exercise
Douligeris et al. Effects of Four Weeks of In-Season Pre-Workout Supplementation on Performance, Body Composition, Muscle Damage, and Health-Related Markers in Basketball Players: A Randomized Controlled Study
Patlar et al. Effect of vitamin C supplementation on lipid peroxidation and lactate levels in individuals performing exhaustion exercise
Forbes Oral l-Arginine Supplementation in Young Males: Endocrinology, Metabolic, and Physiological Responses at Rest and During Exercise
Duttagupta et al. Efficacy of amino acids in sports nutrition-review of clinical evidences
Woitas et al. Major clinical findings of β-alanine in sports performance: a systematic review
Todero THE BENEFITS OF L-GLUTAMINE SUPPLEMENTATION IN ATHLETES.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead